Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
Launched by WESTERN UNIVERSITY, CANADA · May 31, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a ketogenic diet before liver surgery to see if it can help reduce fat in the liver. The ketogenic diet is a low-carb eating plan that may be effective in lowering liver fat, which is important because having too much fat in the liver can lead to complications during surgery. In this study, some participants will follow the ketogenic diet for four weeks leading up to their surgery, while others will receive standard dietary advice. The goal is to find out if the ketogenic diet can improve outcomes for patients undergoing liver surgery for conditions like colorectal cancer that has spread to the liver.
To participate in this trial, you must be at least 18 years old and scheduled for liver surgery due to colorectal liver metastases. You also need to have evidence of fatty liver disease based on imaging or a biopsy. Participants should be comfortable using a mobile app to track their food intake during the study. However, certain individuals will not be eligible, including those with liver fibrosis, cirrhosis, or specific health conditions that might interfere with the diet. This trial is not yet recruiting, but it represents an opportunity to explore how diet can impact surgery outcomes for those with liver issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years of age or older undergoing any type of liver resection (e.g. wedge, formal hepatectomy), either open or laparoscopic, for colorectal liver metastases (CRLM)
- • Patients with evidence of hepatic steatosis on pre-operative imaging (CT or MR) or biopsy.
- • Ability to use an app based nutritional program to track macronutrient uptake throughout the dietary intervention.
- Exclusion Criteria:
- • Patients undergoing liver resection for any other indication
- • Patients on sodium glucose co-transporter 2 (SGLT-2) inhibitors (these are contraindicated with a ketogenic diet).
- • Patients without evidence of hepatic steatosis.
- • Patients with evidence of liver fibrosis or cirrhosis on preoperative bloodwork or imaging.
- • Patients with alcohol-related hepatic steatosis.
- • Patients with a known bleeding disorder.
About Western University, Canada
Western University, located in Canada, is a leading research institution committed to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses the expertise of its faculty and research teams to conduct high-quality studies that address pressing medical challenges. Western University is dedicated to fostering a culture of ethical research practices, ensuring participant safety, and generating impactful findings that contribute to evidence-based medicine and improve patient outcomes. Through its robust infrastructure and commitment to excellence, Western University plays a vital role in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Anton Skaro, MD PhD
Principal Investigator
London Health Sciences Centre/Lawson Health Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported